NASDAQ:VYGR Voyager Therapeutics (VYGR) Stock Price, News & Analysis $9.27 +0.08 (+0.87%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.18▼$9.4850-Day Range$7.52▼$9.1952-Week Range$6.06▼$11.72Volume349,654 shsAverage Volume704,189 shsMarket Capitalization$504.20 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Voyager Therapeutics alerts: Email Address Voyager Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside94.2% Upside$18.00 Price TargetShort InterestBearish7.46% of Shares Sold ShortDividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews Sentiment0.48Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.39) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.35 out of 5 starsMedical Sector335th out of 936 stocksBiological Products, Except Diagnostic Industry50th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageVoyager Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Voyager Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.46% of the outstanding shares of Voyager Therapeutics have been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Voyager Therapeutics has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 71.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.97. Previous Next 2.5 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Voyager Therapeutics this week, compared to 6 articles on an average week.Search Interest4 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows5 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.53% of the stock of Voyager Therapeutics is held by insiders.Percentage Held by Institutions48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Voyager Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to decrease in the coming year, from ($1.39) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is -185.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is -185.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Voyager Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Voyager Therapeutics Stock (NASDAQ:VYGR)Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.Read More VYGR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYGR Stock News HeadlinesJuly 24 at 6:19 AM | msn.comStar Trek: Voyager Lore Changes Forever With One Shocking DeathJuly 23 at 4:01 PM | globenewswire.comVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.July 23 at 1:10 AM | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $18.00 Consensus Target Price from AnalystsJuly 9, 2024 | globenewswire.comVoyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2024 | globenewswire.comVoyager Therapeutics to Present at Multiple Virtual Investor ConferencesJune 13, 2024 | markets.businessinsider.comVoyager Therapeutics Appoints Nathan Jorgensen As New CFO June 13, 2024 | globenewswire.comVoyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial OfficerJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 5, 2024 | seekingalpha.comVoyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment ThesisMay 16, 2024 | finance.yahoo.comVoyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s DiseaseMay 16, 2024 | globenewswire.comVoyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's DiseaseMay 15, 2024 | benzinga.comLatest News for Voyager Therapeutics Stock (NASDAQ:VYGR)May 14, 2024 | finanznachrichten.deVoyager Therapeutics, Inc.: Voyager Therapeutics Reports First Quarter 2024 Financial and Operating ResultsMay 14, 2024 | markets.businessinsider.comPositive Outlook for Voyager Therapeutics: Buy Rating Affirmed Amid Pipeline Progress and Strong Financial PositionMay 14, 2024 | msn.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comQ1 2024 Voyager Therapeutics Inc Earnings CallMay 14, 2024 | finance.yahoo.comVoyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...See More Headlines Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees162Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$30.00 Low Stock Price Target$8.00 Potential Upside/Downside+95.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$132.33 million Net Margins-2.56% Pretax Margin-1.95% Return on Equity-1.28% Return on Assets-0.85% Debt Debt-to-Equity RatioN/A Current Ratio5.64 Quick Ratio5.64 Sales & Book Value Annual Sales$250.01 million Price / Sales2.01 Cash Flow$3.14 per share Price / Cash Flow2.94 Book Value$5.37 per share Price / Book1.72Miscellaneous Outstanding Shares54,390,000Free Float51,930,000Market Cap$502.02 million OptionableOptionable Beta0.96 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Alfred W. Sandrock Jr. (Age 66)M.D., Ph.D., President, CEO & Director Comp: $1.01MMs. Robin Swartz (Age 53)COO, Principal Financial & Accounting Officer and Acting Chief Business Officer Comp: $661.98kMs. Jacquelyn Fahey Sandell Esq. (Age 53)J.D., Chief Legal Officer Comp: $538.16kDr. Krystof Bankiewicz M.D.Ph.D., FounderDr. Guangping Gao Ph.D.Founder & Member of Scientific Advisory BoardDr. Mark A. Kay M.D. (Age 65)Ph.D., Founder Dr. Phillip D. Zamore Ph.D.Founder & Member of Scientific Advisory BoardMr. Todd Carter Ph.D. (Age 54)Chief Scientific Officer Ms. Michelle Quinn SmithChief Human Resources OfficerDr. Maria Lopez-Bresnahan M.B.A.M.D., Senior Vice President of Translational Medicine & Clinical DevelopmentMore ExecutivesKey CompetitorsCabaletta BioNASDAQ:CABAAdverum BiotechnologiesNASDAQ:ADVMbluebird bioNASDAQ:BLUEJounce TherapeuticsNASDAQ:JNCECASI PharmaceuticalsNASDAQ:CASIView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 44,289 shares on 7/26/2024Ownership: 0.541%Patriot Financial Group Insurance Agency LLCBought 127,894 shares on 7/26/2024Ownership: 0.235%Allspring Global Investments Holdings LLCSold 4,532 shares on 7/26/2024Ownership: 0.174%SummerHaven Investment Management LLCBought 1,921 shares on 7/24/2024Ownership: 0.142%Hunter Perkins Capital Management LLCSold 3,150 shares on 7/17/2024Ownership: 0.114%View All Insider TransactionsView All Institutional Transactions VYGR Stock Analysis - Frequently Asked Questions How have VYGR shares performed this year? Voyager Therapeutics' stock was trading at $8.44 at the start of the year. Since then, VYGR shares have increased by 9.8% and is now trading at $9.27. View the best growth stocks for 2024 here. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.24. The business had revenue of $19.52 million for the quarter, compared to analysts' expectations of $10.33 million. Voyager Therapeutics had a negative net margin of 2.56% and a negative trailing twelve-month return on equity of 1.28%. Who are Voyager Therapeutics' major shareholders? Top institutional investors of Voyager Therapeutics include Bank of New York Mellon Corp (0.54%), Patriot Financial Group Insurance Agency LLC (0.24%), Allspring Global Investments Holdings LLC (0.17%) and SummerHaven Investment Management LLC (0.14%). Insiders that own company stock include Neurocrine Biosciences Inc, Rock Ventures Iii LP Third, Ecor1 Capital, Llc, Robert W Hesslein, Robin Swartz, Todd Alfred Carter, Glenn Pierce and Julie Burek. View institutional ownership trends. How do I buy shares of Voyager Therapeutics? Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN) and CRISPR Therapeutics (CRSP). This page (NASDAQ:VYGR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
